Post-GWAS/JJ
Strategies/NNS
./.
====================
Genome-wide/NN
association/NN
(/(
GWA/NN
)/)
studies/NNS
are/VBP
the/DT
method/NN
of/IN
choice/NN
for/IN
discovering/VBG
loci/NNS
associated/VBN
with/IN
common/JJ
diseases/NNS
./.
====================
More/RBR
than/IN
a/DT
thousand/DT
GWA/NN
studies/NNS
have/VBP
reported/VBN
successful/JJ
identification/NN
of/IN
statistically/RB
significant/JJ
association/NN
signals/NNS
in/IN
human/JJ
genomes/NNS
for/IN
a/DT
variety/NN
of/IN
complex/NN
diseases/NNS
./.
====================
In/IN
this/DT
review/NN
,/,
I/NN
discuss/VBP
some/DT
of/IN
the/DT
issues/NNS
related/JJ
to/TO
the/DT
future/JJ
of/IN
GWA/NN
studies/NNS
and/CC
their/PRP$
biomedical/JJ
applications/NNS
./.
====================
Keywords/NNS
:/:
post-GWAS/JJ
,/,
personal/JJ
genomics/NNS
,/,
NGS/NN
,/,
SNPSoon/JJ
after/IN
the/DT
completion/NN
of/IN
the/DT
Human/JJ
Genome/NN
Project/JJ
that/IN
established/VBN
a/DT
reference/RB
human/JJ
genome/NN
sequence/NN
,/,
a/DT
massive/JJ
discovery/RB
of/IN
sequence/NN
variations/NNS
,/,
especially/RB
of/IN
the/DT
type/NN
known/VBN
as/IN
single/JJ
nucleotide/NN
polymorphism/NN
(/(
SNP/NN
)/)
,/,
was/VBD
initiated/VBN
by/IN
the/DT
SNP/NN
Consortium/NN
(/(
TSC/NN
)/)
(/(
Thorisson/NNP
&/CC
Stein/NN
,/,
2003/CD
)/)
./.
====================
After/IN
a/DT
few/JJ
years/NNS
of/IN
efficient/JJ
international/JJ
collaborative/JJ
operations/NNS
,/,
TSC/NN
was/VBD
succeeded/VBN
by/IN
the/DT
International/JJ
HapMap/NN
Project/JJ
,/,
which/WDT
aims/VBZ
to/TO
catalog/NN
common/JJ
variants/NNS
in/IN
our/PRP$
genomes/NNS
and/CC
investigate/VB
the/DT
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
patterns/NNS
between/IN
SNP/NN
markers/NNS
(/(
The/DT
International/JJ
HapMap/NN
Consortium/NN
,/,
2003/CD
)/)
./.
====================
The/DT
knowledge/NN
on/IN
LD/NN
pattern/NN
and/CC
haplotype/JJ
structures/NNS
quickly/RB
helped/VBD
to/TO
design/VB
high/JJ
density/NN
SNP/NN
chips/NNS
for/IN
genome-wide/NN
scanning/NN
of/IN
disease/NN
associated/VBN
loci/NNS
(/(
Wang/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Commercial/JJ
availability/NN
of/IN
such/JJ
SNP/NN
chips/NNS
spurred/VBN
GWA/NN
studies/NNS
of/IN
a/DT
variety/NN
of/IN
common/JJ
diseases/NNS
involving/VBG
many/JJ
genes/NNS
./.
====================
Before/IN
the/DT
advent/JJ
of/IN
GWA/NN
technologies/NNS
,/,
the/DT
complex/NN
diseases/NNS
were/VBD
studied/VBN
by/IN
screening/VBG
genetic/JJ
association/NN
of/IN
the/DT
variants/NNS
within/IN
or/CC
around/IN
a/DT
few/JJ
genes/NNS
of/IN
interest/JJ
,/,
which/WDT
were/VBD
selected/VBN
based/VBN
on/IN
the/DT
researcher/JJ
’/CD
s/NNS
prior/JJ
knowledge/NN
on/IN
the/DT
disease/NN
pathogenesis/NN
./.
====================
Compared/VBN
to/TO
this/DT
‘/NN
candidate/NN
gene/NN
approach/NN
’/CD
,/,
the/DT
GWA/NN
approach/NN
does/VBZ
not/RB
rely/RB
on/IN
a/DT
priori/JJ
biological/JJ
assumption/NN
and/CC
knowledge/NN
on/IN
the/DT
disease/NN
and/CC
thus/RB
has/VBZ
the/DT
potential/JJ
to/TO
detect/VB
novel/JJ
disease/NN
loci/NNS
,/,
providing/VBG
a/DT
new/JJ
insight/NN
and/CC
clues/NNS
on/IN
the/DT
disease/NN
biology/NN
./.
====================
This/DT
advantage/NN
has/VBZ
recently/RB
outweighed/VBN
its/PRP$
high/JJ
cost/JJ
and/CC
GWA/NN
method/NN
has/VBZ
become/VBN
the/DT
method/NN
of/IN
choice/NN
for/IN
studying/VBG
common/JJ
diseases/NNS
involving/VBG
multiple/JJ
genes/NNS
./.
====================
Public/JJ
databases/NNS
now/RB
catalog/NN
more/RBR
than/IN
a/DT
thousand/DT
GWA/NN
publications/NNS
reporting/VBG
intriguing/JJ
association/NN
of/IN
novel/JJ
genomic/JJ
loci/NNS
with/IN
complex/NN
diseases/NNS
(/(
Hindorff/JJ
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
With/IN
these/DT
initial/JJ
successful/JJ
applications/NNS
of/IN
the/DT
GWA/NN
method/NN
,/,
it/PRP
is/VBZ
time/NN
to/TO
plan/VB
the/DT
next/JJ
phase/NN
of/IN
genetic/JJ
association/NN
studies/NNS
,/,
as/IN
we/PRP
now/RB
have/VBP
the/DT
second/JJ
wave/NN
of/IN
Next/RB
Generation/NN
Sequencing/NN
(/(
NGS/NN
)/)
technologies/VBZ
that/DT
are/VBP
much/RB
more/RBR
powerful/JJ
than/IN
previous/JJ
versions/NNS
(/(
Mardis/NNP
,/,
2011/CD
)/)
./.
====================
NGS/NN
will/MD
efficiently/RB
facilitate/VBP
the/DT
detection/NN
of/IN
causal/JJ
mutations/NNS
that/WDT
are/VBP
hidden/JJ
within/IN
the/DT
LD/NN
blocks/VBZ
encompassing/VBG
the/DT
surrogate/NN
markers/NNS
from/IN
GWAS/NN
./.
====================
The/DT
1000/CD
Genomes/NNS
Project/NN
aims/VBZ
to/TO
catalog/NN
less/RBR
frequent/JJ
SNPs/NNS
(/(
~1/CD
%/NN
MAF/NN
)/)
from/IN
the/DT
reference/NN
populations/NNS
(/(
http/NN
:/:
//www.1000genomes/NNS
./.
====================
org/NN
)/)
./.
====================
By/IN
typing/NN
those/DT
mutations/NNS
in/IN
the/DT
study/NN
samples/NNS
,/,
one/CD
can/MD
save/VB
the/DT
resequencing/VBG
efforts/NNS
in/IN
the/DT
followup/JJ
studies/NNS
./.
====================
It/PRP
is/VBZ
certain/JJ
that/DT
those/DT
studies/NNS
involving/VBG
the/DT
ethnic/JJ
groups/NNS
included/VBD
in/IN
the/DT
1000/CD
Genomes/NNS
Project/NN
will/MD
benefit/VB
from/IN
the/DT
project/NN
./.
====================
However/RB
,/,
what/WP
about/RB
the/DT
populations/NNS
not/RB
included/VBN
in/IN
the/DT
project/NN
?/.
====================
In/IN
this/DT
essay/NN
,/,
we/PRP
will/MD
discuss/VB
some/DT
of/IN
the/DT
issues/NNS
concerning/VBG
the/DT
nature/NN
and/CC
future/JJ
of/IN
genomewide/NN
association/NN
study/NN
(/(
GWAS/NN
)/)
,/,
followed/VBN
by/IN
a/DT
suggestion/NN
for/IN
the/DT
next/JJ
phase/NN
research/NN
strategies/NNS
./.
====================
GWAS/NN
utilizes/VBZ
high/JJ
density/NN
SNP/NN
chips/NNS
to/TO
scan/VB
the/DT
genomewide/NN
genotype/NN
profiles/NNS
of/IN
sample/JJ
populations/NNS
./.
====================
The/DT
present/JJ
day/NN
commercial/JJ
SNP/NN
chips/NNS
typically/RB
include/VBP
an/DT
order/NN
of/IN
million/NN
markers/NNS
./.
====================
In/IN
a/DT
typical/JJ
analysis/NN
setting/VBG
,/,
the/DT
genotypephenotype/JJ
association/NN
is/VBZ
assessed/VBN
one/CD
by/IN
one/CD
for/IN
each/DT
marker/NN
./.
====================
This/DT
translates/VBZ
to/TO
millions/NNS
of/IN
independent/JJ
statistical/JJ
tests/NNS
./.
====================
In/IN
order/NN
to/TO
minimize/VB
false/VBP
positives/VBZ
due/JJ
to/TO
multiple/JJ
testing/VBG
,/,
one/CD
typically/RB
imposes/VBZ
a/DT
very/RB
stringent/JJ
cutoff/JJ
for/IN
the/DT
statistical/JJ
significance/NN
level/NN
./.
====================
However/RB
,/,
it/PRP
is/VBZ
still/RB
imaginable/JJ
that/DT
some/DT
false/NN
positives/VBZ
slip/JJ
through/IN
the/DT
threshold/NN
./.
====================
For/IN
example/NN
,/,
there/EX
are/VBP
a/DT
few/JJ
orders/NNS
of/IN
magnitude/NN
more/RBR
markers/NNS
than/IN
samples/NNS
,/,
and/CC
some/DT
peculiar/JJ
sampling/NN
may/MD
cause/VB
bias/NNS
in/IN
the/DT
population/NN
structure/NN
,/,
causing/VBG
spurious/JJ
associations/NNS
./.
====================
In/IN
order/NN
to/TO
overcome/VB
such/JJ
problems/NNS
,/,
the/DT
results/NNS
from/IN
a/DT
GWAS/JJ
are/VBP
typically/RB
reexamined/VBD
by/IN
a/DT
replication/NN
study/NN
employing/VBG
a/DT
dataset/NN
from/IN
independent/JJ
cohorts/NNS
./.
====================
In/IN
general/JJ
strongly/RB
associated/VBN
signals/NNS
are/VBP
well/RB
replicated/VBN
in/IN
other/JJ
populations/NNS
,/,
while/IN
moderate/JJ
ones/NNS
are/VBP
not/RB
so/RB
even/RB
within/IN
the/DT
same/JJ
ethnic/JJ
groups/NNS
./.
====================
We/PRP
call/RB
the/DT
latter/JJ
issue/NN
a/DT
‘/JJ
tip/NN
of/IN
an/DT
iceberg/NN
’/CD
problem/NN
./.
====================
Identification/NN
of/IN
the/DT
hits/NNS
of/IN
moderate/JJ
signals/NNS
tends/VBZ
to/TO
be/VB
sensitive/JJ
to/TO
the/DT
threshold/NN
setting/VBG
./.
====================
While/IN
the/DT
association/NN
signal/NN
of/IN
a/DT
marker/NN
may/MD
be/VB
above/JJ
the/DT
threshold/JJ
in/IN
one/CD
population/NN
,/,
it/PRP
may/MD
be/VB
just/RB
below/IN
the/DT
threshold/JJ
in/IN
another/DT
population/NN
./.
====================
At/IN
the/DT
same/JJ
time/NN
,/,
we/PRP
miss/VBP
bulk/NN
of/IN
the/DT
genuine/JJ
signals/NNS
below/IN
the/DT
threshold/NN
./.
====================
This/DT
is/VBZ
similar/JJ
to/TO
the/DT
situation/NN
observed/VBN
with/IN
the/DT
‘/NN
tip/NN
of/IN
an/DT
iceberg/NN
’/CD
./.
====================
Besides/RB
the/DT
difficulty/NN
in/IN
replicating/VBG
the/DT
original/JJ
GWAS/NN
result/NN
in/IN
independent/JJ
cohorts/NNS
,/,
small/JJ
number/NN
of/IN
strong/JJ
signal/NN
observed/VBN
in/IN
GWAS/NN
hinders/NNS
both/CC
rich/JJ
biological/JJ
interpretation/NN
of/IN
the/DT
GWAS/NN
results/NNS
and/CC
reasonable/JJ
risk/NN
prediction/NN
based/VBN
on/IN
genotypes/NNS
./.
====================
This/DT
posed/JJ
a/DT
serious/JJ
threat/NN
to/TO
GWAS/NN
and/CC
has/VBZ
been/VBN
the/DT
basis/NN
of/IN
wide-spread/JJ
pessimism/NN
on/IN
the/DT
prospect/NN
of/IN
common/JJ
disease/NN
studies/NNS
./.
====================
In/IN
late/JJ
2009/CD
,/,
Manolio/JJ
et/FW
al/JJ
./.
====================
published/VBN
an/DT
article/NN
critically/RB
reviewing/VBG
the/DT
issue/NN
of/IN
poor/JJ
ability/NN
to/TO
explain/VB
phenotypic/JJ
variation/NN
based/VBN
on/IN
genotypes/NNS
(/(
Manolio/NNP
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
One/CD
of/IN
the/DT
traits/NNS
given/VBN
as/IN
an/DT
example/NN
in/IN
the/DT
review/NN
article/NN
was/VBD
human/JJ
height/NN
./.
====================
The/DT
genetic/JJ
contribution/NN
to/TO
its/PRP$
variation/NN
is/VBZ
known/VBN
to/TO
be/VB
around/IN
80/CD
%/NN
,/,
while/IN
the/DT
combined/JJ
alleles/NNS
identified/VBD
thus/RB
far/RB
explained/VBN
only/RB
5/CD
%/NN
of/IN
the/DT
phenotype/NN
variance/NN
,/,
the/DT
rest/JJS
being/VBG
claimed/VBN
as/IN
missing/JJ
heritability/NN
./.
====================
The/DT
review/NN
also/RB
speculated/VBN
the/DT
potential/JJ
factors/NNS
contributing/VBG
to/TO
the/DT
missing/JJ
heritability/NN
./.
====================
For/IN
example/NN
,/,
they/PRP
posit/VBP
that/DT
rare/JJ
or/CC
structural/JJ
variants/NNS
are/VBP
not/RB
well/RB
represented/VBN
in/IN
the/DT
commercial/JJ
SNP/NN
chips/NNS
,/,
and/CC
that/IN
modeling/VBG
epistatis/NN
of/IN
gene-gene/NN
interaction/NN
or/CC
incorporation/NN
of/IN
environmental/JJ
factors/NNS
may/MD
be/VB
necessary/JJ
./.
====================
Besides/RB
,/,
they/PRP
also/RB
argued/VBD
that/IN
there/EX
may/MD
be/VB
many/JJ
more/RBR
weaker/JJR
signals/NNS
yet/RB
to/TO
be/VB
found/VBN
./.
====================
In/IN
order/NN
to/TO
discover/JJ
them/PRP
,/,
much/RB
larger/JJR
sample/NN
size/NN
will/MD
be/VB
required/VBN
./.
====================
Yang/NN
et/FW
al/JJ
./.
====================
reported/VBN
a/DT
simulation/JJ
result/NN
claiming/VBG
that/DT
all/DT
the/DT
SNPs/NNS
in/IN
the/DT
GWAS/NN
chip/NN
would/MD
collectively/RB
explain/VBP
about/RB
half/RB
of/IN
the/DT
human/JJ
height/NN
variation/NN
(/(
Yang/NNP
et/FW
al./FW
,/,
2010/CD
)/)
./.
====================
In/IN
fact/NN
,/,
a/DT
large-scale/JJ
meta/NN
analysis/NN
combining/VBG
46/CD
data/NNS
sets/NNS
comprising/VBG
183,727/CD
European/JJ
individuals/NNS
identified/VBD
hundreds/VBZ
more/RBR
variants/NNS
related/JJ
to/TO
human/JJ
height/NN
and/CC
could/MD
explain/VB
up/IN
to/TO
10/CD
%/NN
of/IN
its/PRP$
variation/NN
(/(
GIANT/NN
Consortium/NN
,/,
2010/CD
)/)
./.
====================
This/DT
work/NN
confirmed/VBD
the/DT
earlier/RBR
premise/RB
that/DT
there/EX
are/VBP
many/JJ
more/RBR
weaker/JJR
signals/NNS
yet/RB
to/TO
be/VB
found/VBN
and/CC
one/CD
way/NN
to/TO
enhance/VB
the/DT
statistical/JJ
power/JJR
to/TO
discover/RB
them/PRP
is/VBZ
by/IN
increasing/VBG
the/DT
sample/JJ
size/NN
./.
====================
Although/IN
it/PRP
is/VBZ
a/DT
promising/JJ
option/NN
,/,
not/RB
every/RB
trait/VBP
can/MD
be/VB
studied/VBN
in/IN
this/DT
way/NN
./.
====================
While/IN
it/PRP
is/VBZ
still/RB
a/DT
long/JJ
way/NN
to/TO
go/VB
for/IN
useful/JJ
risk/NN
prediction/NN
based/VBN
on/IN
genotypes/NNS
,/,
the/DT
hefty/NN
number/NN
of/IN
genes/NNS
whose/WP$
genetic/JJ
associations/NNS
are/VBP
newly/RB
identified/VBN
by/IN
GWAS/NN
can/MD
provide/VB
novel/JJ
insights/NNS
regarding/VBG
trait/VBP
development/NN
or/CC
pathogenesis/NN
of/IN
disease/NN
traits/VBZ
./.
====================
If/IN
hundreds/VBZ
of/IN
genes/NNS
are/VBP
identified/VBN
by/IN
GWAS/NN
,/,
gene/NN
ontology/NN
terms/NNS
or/CC
pathways/NNS
enriched/VBN
among/IN
them/PRP
can/MD
be/VB
identified/VBN
in/IN
a/DT
similar/JJ
manner/NN
as/IN
well/RB
established/VBN
in/IN
gene/NN
expression/NN
profile/NN
analysis/NN
(/(
Huang/NNP
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
This/DT
method/NN
is/VBZ
not/RB
applicable/JJ
if/IN
only/RB
a/DT
handful/JJ
of/IN
genes/NNS
are/VBP
identified/VBN
from/IN
GWAS/NN
./.
====================
In/IN
such/JJ
cases/NNS
,/,
geneset/NN
analysis/NN
(/(
GSA/NN
)/)
may/MD
be/VB
considered/VBN
(/(
Nam/NN
&/CC
Kim/NN
,/,
2008/CD
)/)
./.
====================
GSA/NN
is/VBZ
well/RB
established/VBN
in/IN
the/DT
area/NN
of/IN
gene/NN
expression/NN
analysis/NN
./.
====================
Instead/RB
of/IN
selecting/VBG
a/DT
set/NN
of/IN
genes/NNS
passing/VBG
a/DT
certain/JJ
cutoff/JJ
and/CC
looking/VBG
for/IN
functional/JJ
terms/NNS
commonly/RB
shared/VBN
by/IN
the/DT
gene/NN
set/NN
,/,
GSA/NN
checks/NNS
a/DT
setwise/JJ
association/NN
score/RB
where/WRB
the/DT
contribution/NN
by/IN
all/DT
the/DT
member/NN
genes/NNS
in/IN
the/DT
geneset/NN
are/VBP
summarized/VBN
regardless/RB
of/IN
their/PRP$
significance/NN
level/NN
./.
====================
It/PRP
is/VBZ
important/JJ
not/RB
to/TO
filter/NN
certain/JJ
markers/NNS
or/CC
genes/NNS
based/VBN
on/IN
their/PRP$
significance/NN
level/NN
./.
====================
The/DT
rationale/JJ
is/VBZ
as/IN
follows/VBZ
:/:
if/IN
one/CD
wants/NNS
to/TO
calculate/JJ
a/DT
mean/JJ
property/NN
and/CC
removes/VBZ
hits/VBZ
with/IN
low/JJ
score/NN
values/NNS
,/,
the/DT
mean/JJ
would/MD
be/VB
unnecessarily/RB
inflated/JJ
./.
====================
If/IN
a/DT
biological/JJ
pathway/NN
or/CC
functional/JJ
module/NN
plays/VBZ
a/DT
significant/JJ
role/NN
in/IN
the/DT
trait/NN
development/NN
,/,
its/PRP$
setwise/JJ
association/NN
score/RB
would/MD
be/VB
significantly/RB
higher/JJR
than/IN
those/DT
of/IN
the/DT
nonassociated/JJ
groups/NNS
(/(
Nam/NN
et/FW
al./FW
,/,
2010/CD
)/)
./.
====================
Even/RB
if/IN
individual/JJ
effect/NN
or/CC
signal/NN
may/MD
not/RB
be/VB
strong/JJ
enough/IN
to/TO
pass/VB
the/DT
threshold/JJ
,/,
the/DT
collective/JJ
contributions/NNS
from/IN
those/DT
genes/NNS
may/MD
add/VB
up/IN
to/TO
surpass/VB
the/DT
random/JJ
expectation/NN
./.
====================
This/DT
approach/NN
offers/VBZ
a/DT
benefit/NN
of/IN
reaching/VBG
out/RP
the/DT
‘/NN
core/NN
of/IN
an/DT
iceberg/NN
’/CD
without/IN
increasing/VBG
the/DT
sample/NN
size/NN
./.
====================
Recently/RB
,/,
Wang/NNP
et/FW
al./FW
,/,
2010./CD
reviewed/VBD
various/JJ
computational/JJ
methods/NNS
that/DT
implemented/VBD
pathway/NN
analysis/NN
approach/NN
for/IN
GWAS/NN
(/(
Wang/NNP
et/FW
al./FW
,/,
2010/CD
)/)
./.
====================
They/PRP
suggest/VBP
that/IN
pathway/NN
analysis/NN
may/MD
allow/VB
rich/JJ
description/NN
of/IN
the/DT
biological/JJ
mechanism/NN
behind/VBP
the/DT
trait/NN
development/NN
in/IN
an/DT
unprecedented/JJ
manner/NN
and/CC
has/VBZ
the/DT
potential/JJ
to/TO
suggest/VB
therapeutic/JJ
or/CC
diagnostic/JJ
targets/NNS
without/IN
delving/VBG
into/IN
the/DT
specific/JJ
identification/NN
of/IN
causal/JJ
variants/NNS
./.
====================
Eric/JJ
Lander/NN
,/,
in/IN
his/DT
review/NN
of/IN
celebrating/JJ
tenth/DT
anniversary/JJ
of/IN
human/JJ
genome/NN
sequencing/NN
,/,
also/RB
illustrated/VBD
several/JJ
successful/JJ
examples/NNS
along/IN
this/DT
line/NN
where/WRB
GWAS/NN
help/VB
to/TO
advance/VB
the/DT
biomedical/JJ
applications/NNS
(/(
Lander/NN
,/,
2011/CD
)/)
./.
====================
If/IN
the/DT
biological/JJ
mechanisms/NNS
are/VBP
common/JJ
for/IN
the/DT
same/JJ
traits/VBZ
regardless/RB
of/IN
populations/NNS
,/,
GSA/NN
would/MD
yield/VB
highly/RB
replicating/VBG
results/NNS
,/,
even/RB
in/IN
the/DT
cases/NNS
where/WRB
individual/JJ
markers/NNS
do/VBP
not/RB
show/VB
correlative/JJ
association/NN
across/IN
different/JJ
populations/NNS
./.
====================
It/PRP
would/MD
be/VB
interesting/JJ
to/TO
see/VB
whether/IN
this/DT
is/VBZ
indeed/RB
the/DT
case/NN
with/IN
multipopulation/JJ
meta/NN
analysis/NN
data/NNS
sets/NNS
./.
====================
It/PRP
is/VBZ
also/RB
informative/JJ
to/TO
know/VB
to/TO
what/DT
extent/NN
of/IN
ethnic/JJ
groups/NNS
we/PRP
would/MD
expect/VB
that/DT
GSA/NN
give/VBP
overlapping/VBG
results/NNS
./.
====================
For/IN
example/NN
,/,
may/MD
such/JJ
a/DT
high/JJ
overlap/IN
be/VB
expected/VBN
within/IN
Asian/JJ
pop/NN
ulations/NNS
only/RB
or/CC
even/RB
among/IN
Asian/JJ
and/CC
Europeans/NNS
?/.
====================
Now/RB
there/EX
are/VBP
even/RB
bolder/JJR
approaches/NNS
that/WDT
intend/VBP
to/TO
integrate/VB
systems/NNS
biology/NN
to/TO
genetics/NNS
,/,
called/VBN
systems/NNS
genetics/NNS
(/(
Butte/NNP
et/FW
al./FW
,/,
2011/CD
)/)
./.
====================
Instead/RB
of/IN
scoring/VBG
a/DT
collective/JJ
association/NN
of/IN
a/DT
predefined/JJ
set/NN
of/IN
genes/NNS
,/,
this/DT
new/JJ
approach/NN
tests/NNS
the/DT
association/NN
of/IN
protein/NN
interaction/NN
or/CC
gene/NN
regulatory/JJ
networks/NNS
./.
====================
While/IN
the/DT
two/CD
approaches/NNS
may/MD
look/VB
similar/JJ
,/,
there/EX
is/VBZ
an/DT
important/JJ
distinction/NN
./.
====================
The/DT
former/JJ
mainly/RB
relies/VBZ
on/IN
evidence/NN
collected/VBD
from/IN
literature/NN
,/,
and/CC
thus/RB
of/IN
highly/RB
reliable/JJ
,/,
but/CC
their/PRP$
coverage/JJ
is/VBZ
rather/RB
low/JJ
and/CC
the/DT
interaction/NN
context/NN
between/IN
genes/NNS
are/VBP
missing/VBG
for/IN
some/DT
gene/NN
sets/NNS
such/JJ
as/IN
those/DT
based/VBN
on/IN
gene/NN
ontology/RB
or/CC
molecular/JJ
signatures/NNS
./.
====================
The/DT
latter/JJ
may/MD
have/VB
the/DT
advantage/NN
of/IN
testing/VBG
network/NN
properties/NNS
that/DT
are/VBP
likely/JJ
dependent/JJ
on/IN
the/DT
context/NN
of/IN
the/DT
trait/NN
,/,
facilitated/VBN
by/IN
the/DT
integration/NN
of/IN
various/JJ
omics/NNS
profiling/VBG
data/NNS
./.
====================
Tom/RB
Hudson/NNP
,/,
President/JJ
and/CC
Scientific/JJ
Director/NN
,/,
Ontario/NNP
Institute/RB
for/IN
Cancer/NN
Research/NNP
,/,
Toronto/RB
,/,
Ontario/NNP
,/,
Canada/NN
,/,
wrote/RB
in/IN
an/DT
essay/JJ
celebrating/JJ
tenth/DT
anniversary/JJ
of/IN
genome/NN
sequencing/NN
that/IN
he/RB
would/MD
invest/VB
heavily/RB
in/IN
developing/VBG
large/JJ
clinical/JJ
resources/NNS
if/IN
he/RB
could/MD
move/VB
the/DT
clock/NN
back/RB
to/TO
2001/CD
when/WRB
the/DT
initial/JJ
draft/NN
of/IN
the/DT
human/JJ
“/NNP
reference/RB
”/NNP
genome/NN
sequence/NN
was/VBD
published/VBN
(/(
Hudson/NNP
,/,
2011/CD
)/)
./.
====================
Once/RB
integrated/VBN
with/IN
genomic/JJ
technologies/NNS
the/DT
cohorts/NNS
annotated/JJ
with/IN
ten/CD
years/NNS
of/IN
detailed/JJ
clinical/JJ
history/JJ
would/MD
have/VBP
profound/VBN
effect/NN
in/IN
understanding/VBG
disease/NN
progression/NN
./.
====================
Introduction/NN
of/IN
NGS/NN
technologies/NNS
has/VBZ
sparked/VBN
the/DT
genome/NN
sequencing/NN
of/IN
individuals/NNS
(/(
Nature/NN
Editorial/JJ
,/,
2010/CD
)/)
./.
====================
There/EX
are/VBP
now/RB
several/JJ
so-called/JJ
personal/JJ
genome/NN
projects/NNS
,/,
such/JJ
as/IN
the/DT
1000/CD
Genomes/NNS
Project/NN
and/CC
the/DT
Personal/JJ
Genome/NN
Project/NN
(/(
http/NN
:/:
//www/JJ
./.
====================
personalgenomes/NNS
./.
====================
org/NN
)/)
./.
====================
In/IN
the/DT
era/NN
of/IN
personal/JJ
genomics/NNS
,/,
what/WP
would/MD
be/VB
the/DT
future/JJ
of/IN
GWAS/NN
?/.
====================
Some/DT
think/NN
that/DT
GWAS/NN
will/MD
be/VB
superseded/VBN
by/IN
variant/JJ
profiling/VBG
based/VBN
on/IN
NGS/NN
./.
====================
Certainly/RB
high/JJ
penetrant/JJ
,/,
monogenic/JJ
,/,
Mendelian/JJ
diseases/NNS
would/MD
benefit/VB
greatly/RB
from/IN
NGS/NN
,/,
where/WRB
comparative/JJ
sequencing/NN
of/IN
affected/VBN
and/CC
unaffected/JJ
from/IN
the/DT
closely/RB
related/JJ
families/NNS
would/MD
reveal/VB
the/DT
disease/NN
mutations/NNS
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
common/JJ
,/,
complex/NN
diseases/NNS
require/VBP
a/DT
large/JJ
number/NN
of/IN
unrelated/JJ
population/NN
samples/NNS
to/TO
locate/VB
the/DT
statistically/RB
confident/JJ
disease-causing/VBG
loci/NNS
./.
====================
The/DT
current/JJ
NGS/NN
technologies/NNS
are/VBP
too/RB
expensive/JJ
to/TO
replace/VB
the/DT
traditional/JJ
SNP/NN
chips/NNS
in/IN
population/NN
genotyping/VBG
./.
====================
In/IN
addition/NN
,/,
computational/JJ
cost/JJ
and/CC
time/NN
for/IN
handling/NN
whole/JJ
genome/NN
NGS/NN
data/NNS
for/IN
the/DT
large/JJ
number/NN
of/IN
samples/NNS
required/VBN
in/IN
GWAS/NN
would/MD
be/VB
prohibitive/JJ
at/IN
the/DT
moment/NN
and/CC
within/IN
the/DT
foreseeable/JJ
future/JJ
./.
====================
Ideally/RB
sequencing/NN
technology/NN
can/MD
detect/VB
novel/JJ
mutations/NNS
and/CC
profile/NN
known/VBN
variants/NNS
in/IN
one/CD
shot/JJ
./.
====================
However/RB
,/,
a/DT
two/CD
step/JJ
process/NN
would/MD
be/VB
more/RBR
practical/JJ
:/:
(/(
1/CD
)/)
discovering/VBG
novel/JJ
mutations/NNS
by/IN
sequencing/VBG
;/:
(/(
2/CD
)/)
followup/JJ
genotyping/VBG
of/IN
the/DT
variants/NNS
by/IN
chip/NN
technology/NN
./.
====================
One/CD
of/IN
the/DT
aims/NNS
of/IN
the/DT
1000/CD
Genomes/NNS
Project/NN
is/VBZ
to/TO
provide/VB
reference/NN
variant/JJ
profiles/NNS
for/IN
HapMap/NN
populations/NNS
./.
====================
For/IN
a/DT
given/VBN
GWAS/NN
,/,
one/CD
can/MD
look/VB
up/IN
the/DT
database/NN
to/TO
pick/VB
up/IN
the/DT
potential/JJ
variants/NNS
within/IN
the/DT
LD/NN
block/VBP
of/IN
the/DT
association/NN
signals/NNS
./.
====================
The/DT
commondisease/commonvariant/JJ
hypothesis/NN
tells/NNS
that/DT
if/IN
a/DT
diseasecausing/JJ
mutation/NN
has/VBZ
occurred/VBN
one/CD
time/NN
in/IN
human/JJ
history/JJ
at/IN
a/DT
certain/JJ
haplotype/JJ
,/,
it/PRP
would/MD
be/VB
inherited/VBN
by/IN
the/DT
descendants/NNS
who/WP
carry/VBP
the/DT
haplotype/JJ
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
those/DT
who/WP
do/VBP
not/RB
carry/VB
this/DT
haplotype/NN
would/MD
be/VB
unaffected/JJ
by/IN
the/DT
disease/NN
./.
====================
While/IN
subsequent/JJ
recombination/NN
would/MD
diversify/VB
the/DT
overall/JJ
haplotype/NN
structure/NN
,/,
the/DT
core/NN
haplotype/NN
around/IN
the/DT
diseasecausing/JJ
variant/JJ
would/MD
be/VB
conserved/VBN
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
important/JJ
to/TO
identify/VB
the/DT
haplotypes/NNS
associated/VBN
with/IN
the/DT
trait/NN
of/IN
interest/NN
through/IN
GWAS/NN
and/CC
to/TO
infer/VB
the/DT
potential/JJ
diseasecausing/VBG
variants/NNS
from/IN
the/DT
NGS/NN
data/NNS
that/IN
match/VBP
those/DT
haplotypes/NNS
./.
====================
The/DT
success/NN
of/IN
this/DT
approach/NN
is/VBZ
then/RB
dependent/JJ
on/IN
whether/IN
the/DT
1000/CD
Genomes/NNS
Project/JJ
covers/NNS
the/DT
samples/NNS
whose/WP$
haplotype/JJ
structures/NNS
are/VBP
compatible/JJ
with/IN
those/DT
of/IN
our/PRP$
GWAS/NN
subjects/NNS
./.
====================
At/IN
the/DT
moment/NN
,/,
the/DT
1000/CD
Genomes/NNS
Project/JJ
is/VBZ
partially/RB
complete/JJ
and/CC
we/PRP
need/VBD
to/TO
wait/VB
more/RBR
to/TO
answer/JJR
this/DT
question/NN
for/IN
nonHapMap/JJ
population/NN
GWAS/NN
./.
====================
If/IN
we/PRP
focus/VBP
our/PRP$
attention/NN
to/TO
Korean/JJ
GWAS/NN
issues/NNS
,/,
several/JJ
options/NNS
can/MD
be/VB
suggested/VBN
./.
====================
Since/IN
Korea/NN
is/VBZ
geographically/RB
between/IN
China/NN
and/CC
Japan/NNP
and/CC
genetically/RB
also/RB
Koreans/NNS
are/VBP
in/IN
between/IN
Chinese/JJ
and/CC
Japanese/JJ
populations/NNS
,/,
we/PRP
can/MD
wait/VB
until/IN
the/DT
1000/CD
Genomes/NNS
Project/JJ
produce/VBP
sufficiently/RB
accurate/JJ
and/CC
useful/JJ
data/NNS
for/IN
both/DT
Chinese/JJ
and/CC
Japanese/JJ
populations/NNS
./.
====================
Alternatively/RB
,/,
we/PRP
can/MD
pursue/VB
producing/VBG
Korean/JJ
reference/VBP
whole/JJ
genome/NN
sequences/NNS
,/,
for/IN
which/WDT
the/DT
sampling/JJ
object/NN
should/MD
be/VB
to/TO
maximize/VB
the/DT
genetic/JJ
diversity/NN
among/IN
Koreans/NNS
./.
====================
The/DT
existing/VBG
GWAS/NN
genotype/NN
data/NNS
would/MD
facilitate/VB
such/JJ
a/DT
sample/JJ
selection/NN
process/NN
./.
====================
In/IN
fact/NN
these/DT
two/CD
options/NNS
are/VBP
not/RB
mutually/RB
exclusive/JJ
,/,
rather/RB
complementary/JJ
./.
====================
For/IN
example/NN
,/,
comparison/NN
of/IN
Korean/JJ
reference/VBP
genomes/NNS
with/IN
those/DT
from/IN
the/DT
Chinese/JJ
and/CC
Japanese/JJ
of/IN
the/DT
1000/CD
Genomes/NNS
Project/JJ
would/MD
tell/NN
us/PRP
how/WRB
much/RB
reference/VBP
sequencing/NN
among/IN
Koreans/NNS
is/VBZ
necessary/JJ
./.
====================
There/EX
has/VBZ
been/VBN
widely/RB
known/VBN
and/CC
somewhat/RB
accepted/VBN
skepticism/NN
on/IN
GWAS/NN
./.
====================
However/RB
,/,
the/DT
recent/JJ
progresses/NNS
reshed/VBD
light/NN
on/IN
its/PRP$
potential/JJ
./.
====================
Recently/RB
NIH/NN
and/CC
NCI/NN
,/,
USA/NN
funded/VBD
several/JJ
projects/NNS
called/VBN
the/DT
PostGWA/JJ
Initiative/JJ
(/(
http/NN
:/:
//grants/NNS
./.
====================
nih/DT
./.
====================
gov/grants/guide/rfafiles/RFA/NN
CA-09-002/NN
./.
====================
html/NN
)/)
./.
====================
These/DT
projects/NNS
(/(
Monteiro/NNP
et/FW
al./FW
,/,
2010/CD
)/)
,/,
focusing/VBG
on/IN
GWA/NN
studies/NNS
of/IN
cancers/NNS
,/,
follow/VBP
up/IN
the/DT
GWAS/NN
outcomes/NNS
to/TO
pin-point/VB
the/DT
causal/JJ
variants/NNS
and/CC
understand/VB
how/WRB
they/PRP
influence/VBP
disease/NN
development/NN
and/CC
progression/NN
./.
====================
Bioinformatic/JJ
computational/JJ
tools/NNS
would/MD
play/VB
important/JJ
roles/NNS
in/IN
prioritizing/VBG
the/DT
potential/JJ
causal/JJ
variants/NNS
through/IN
the/DT
prediction/NN
of/IN
the/DT
functional/JJ
consequence/NN
of/IN
each/DT
variant/JJ
and/CC
the/DT
analysis/NN
of/IN
the/DT
affected/VBN
pathways/NNS
./.
====================
Experimental/JJ
validations/NNS
employing/VBG
both/CC
omics/NNS
profiling/VBG
and/CC
animal/NN
models/NNS
are/VBP
also/RB
planned/VBD
./.
====================
Much/RB
of/IN
the/DT
idea/NN
laid/JJ
out/RP
in/IN
the/DT
projects/NNS
share/VBP
the/DT
same/JJ
spirit/NN
with/IN
this/DT
essay/NN
./.
====================
This/DT
work/NN
was/VBD
supported/VBN
by/IN
Basic/JJ
Science/NNP
Research/NN
Program/NN
through/IN
the/DT
National/JJ
Research/NN
Foundation/NN
of/IN
Korea/NN
(/(
NRF/NN
)/)
funded/VBD
by/IN
the/DT
Ministry/NN
of/IN
Education/NN
,/,
Science/NNP
and/CC
Technology/NN
(/(
NRF-2010-0021811/NN
)/)
./.
====================
